PTC Therapeutics, Inc. - Common Stock (PTCT)

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.

Focused on rare disease therapies, this biotech company reported a significant insider sale amid strong recent share price gains.

PTC Therapeutics offers strong growth and solid financials at a fair price, making it an attractive stock for investors seeking affordable expansion opportunities.

A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

PTC Therapeutics (PTCT) shows explosive earnings growth of 277% and strong technicals, presenting a high-momentum investment opportunity.

Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage clinical trial. The biopharmaceutical company revealed that its Phase 3 ESSENCE study, evaluating the efficacy of its Duchenne muscular dystrophy (DMD) therapies Amondys

PTC Therapeutics (PTCT) shows strong growth with 96% revenue surge and a bullish technical breakout pattern, making it a compelling biotech stock.

PTC Therapeutics offers strong growth and attractive valuation metrics, making it a compelling affordable growth stock for investors seeking biotech opportunities.

PTC Therapeutics (PTCT) offers strong growth with a 96% revenue surge, yet trades at a reasonable P/E of 10.94, making it a compelling GARP investment.

PTC Therapeutics (PTCT) combines explosive sales growth and strong earnings with an attractive valuation and bullish technical setup for a compelling investment profile.

PTC Therapeutics (PTCT) offers strong growth & attractive valuation. With revenue up 96% and a low P/E of 10.29, it's a top affordable growth stock pick in biotech.

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.

An upbeat presentation helped highlight the potential for the company's leading drug to be commercially successful.

PTC Therapeutics is stuck with uncertainty stretching through 2030. Here's why the stock remains a long-term avoid.

Discover PTC Therapeutics (PTCT), an affordable growth stock with strong revenue & EPS growth, low P/E ratio, and solid profit margins in the biotech sector.

FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring another controlled trial.